Negative T790M Mutation and Met Amplification

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

HB
HaiHe BiopharmaChina - Shanghai
1 program
1
GlumetinibPhase 1/2Small Molecule1 trial
Active Trials
NCT04338243UnknownEst. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HaiHe BiopharmaGlumetinib

Clinical Trials (1)

NCT04338243HaiHe BiopharmaGlumetinib

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Start: Nov 2019Est. completion: Dec 2020
Phase 1/2Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space